{"id":"NCT01652664","sponsor":"Alcon Research","briefTitle":"Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","officialTitle":"A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2012-07-30","resultsPosted":"2015-04-13","lastUpdate":"2015-07-23"},"enrollment":184,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Glaucoma","Elevated IOP in Pediatric Patients","Ocular Hypertension in Pediatric Patients"],"interventions":[{"type":"DRUG","name":"Travoprost 0.004% PQ ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"Timolol, 0.5% or 0.25% ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"Travoprost Vehicle","otherNames":[]}],"arms":[{"label":"Travoprost","type":"EXPERIMENTAL"},{"label":"Timolol","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma patients.","primaryOutcome":{"measure":"Mean Change From Baseline in IOP at Month 3","timeFrame":"Baseline (Day 0), Month 3","effectByArm":[{"arm":"Travoprost","deltaMin":-5.4,"sd":0.98},{"arm":"Timolol","deltaMin":-5.3,"sd":0.93}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":184},"commonTop":["Ocular hyperaemia","Headache","Growth of eyelashes","Conjunctival hyperaemia"]}}